2017 American Society of Clinical Oncology Annual Meeting*

Look for these important studies at the upcoming Clinical Oncology meeting in Chicago. Be sure to also check our Web site frequently for downloadable PowerPoint slides featuring key presented data.

Sara Hurvitz, MD, FACP Released: May 31, 2017

Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile.

Significantly improved PFS and ORR observed with addition of lapatinib to trastuzumab plus investigator-selected aromatase inhibitor.

Pembrolizumab monotherapy was well tolerated and active in a subset of pretreated metastatic TNBC patients, with promising preliminary survival results observed in patients with CR, PR, or SD.

The addition of ipatasertib to paclitaxel improved PFS for patients with metastatic TNBC, with the greatest benefit observed in a prespecified subgroup analysis of patients with PIK3CA/AKT1/PTEN-altered tumors.

Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing.

TC noninferior to EC→T in patients with high-risk HER2-negative early BC with comparable 5-year DFS (90%), OS (95%), and reduced toxicity.

The addition of pembrolizumab to neoadjuvant T → AC “graduated” I-SPY 2 for efficacy, approximately tripling the estimated pCR in TNBC and in HR+/HER2- EBC.

Comparable pCR, less febrile neutropenia and LVEF decline with anthracycline-free vs anthracycline-containing neoadjuvant CT when paired with dual HER2 blockade.

Addition of veliparib and carboplatin to neoadjuvant T → AC did not increase pCR rate over carboplatin plus T → AC alone.

Review the latest developments in breast cancer care from ASCO 2017 with these expert insights from Sara Hurvitz, MD, FACP, and Kathy D. Miller, MD.

Sara Hurvitz, MD, FACP Kathy D. Miller, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 16, 2017 Expired: No longer available for credit

Study data showed significantly prolonged PFS and a lower rate of high-grade adverse events with olaparib monotherapy vs CT.

Pertuzumab addition significantly reduced risk of recurrence vs current standard.

In these subanalyses of the CALGB/SWOG 80405 trial, tumor sidedness was a prognostic factor independent of other molecular features, and BRAF status was also a strong prognostic marker for patients with mCRC receiving first-line treatment.

In this open-label phase II study, addition of vemurafenib associated with significantly improved PFS and clinical activity in BRAF V600E mCRC patients previously treated with systemic chemotherapy.

Next-generation sequencing of circulating tumor DNA revealed complex mutational changes with panitumumab treatment.

Lenvatinib demonstrated noninferior OS, significantly increased PFS, TTP, and ORR vs sorafenib with expected safety profile.

No significant difference in OS noted, but patients in treated population who received SIRT experienced higher ORR and fewer AEs/serious AEs vs those who received sorafenib.

Pembrolizumab well tolerated, produced durable responses in patients with pretreated, advanced gastric/GEJ cancer, with highest responses in PD-L1–positive subgroup.

In this trial, adjuvant capecitabine improved survival vs placebo in patients with resected biliary cancer with modest toxicity and no reduction in quality of life.

Addition of PEGPH20 to nab-paclitaxel/gemcitabine improved PFS in the full study population with the greatest improvement in the patients with high tumor levels of hyaluronan.

AG-120 was associated with fatigue and gastrointestinal toxicities and prolonged stable disease.

In this text module and accompanying downloadable slideset, experts Steven J. Cohen, MD, and Alan P. Venook, MD, review the most clinically relevant study results presented at Clinical Oncology 2017 in colorectal cancer, hepatocellular cancer, gastric cancers, biliary cancers, and pancreatic cancer.

Steven J. Cohen, MD Alan P. Venook, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 7, 2017 Expired: No longer available for credit

In this analysis of 6 phase III trials, DFS and neuropathy rates varied with adjuvant oxaliplatin duration among patients based on risk factors and regimen.

Significant survival benefit and favorable safety profile with pembrolizumab vs chemotherapy maintained in extended follow-up.

ORR increased from previous report with longer follow-up and 18-gene GEP score significantly associated with response.

In patients with advanced urothelial carcinoma, epacadostat plus pembrolizumab well tolerated, with ORR of 35% (DCR: 53%) in this patient cohort.

Adjuvant pazopanib at 600 mg after nephrectomy did not prolong DFS compared with placebo in patients with locally advanced RCC.

Epacadostat plus pembrolizumab safe, active in patients with advanced RCC with 47% ORR in patients who received ≤ 1 previous line of therapy.

In the phase III LION trial, systemic pelvic and para-aortic lymphadenectomy offered no survival benefit and increased postoperative morbidity and mortality in patients with advanced ovarian cancer, macroscopic complete resection, and clinically/radiographically negative lymph nodes.

Combination RT + CT improved 5-year failure-free survival by 11% in patients with stage III disease.

Nivolumab monotherapy active with a manageable safety profile in recurrent/metastatic cervical, vaginal, or vulvar cancer regardless of PD-L1 expression.

No detrimental effect on HRQoL, significant improvement in patient-centered benefits with olaparib vs placebo despite higher olaparib-associated toxicity.

Momelotinib achieved noninferior spleen response vs rituximab, with inferior total symptom response rate.

Results from this phase III study reveal comparable splenic response rate but improved symptomatic response and transfusion independence rates with momelotinib vs BAT.

Study investigators conclude that molecular response may predict durable clinical benefit in patients treated with gilteritinib.

Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events.

Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden.

BR associated with significantly increased 5-year PFS, duration of response, and event-free survival vs R-CHOP/R-CVP in overall patient population, particularly in MCL subgroup.

Rituximab plus lenalidomide showed activity, tolerable safety in patients with R/R follicular lymphoma, including those with double-refractory disease or early relapse on prior therapy.

The addition of ublituximab to ibrutinib improved ORR vs ibrutinib alone with a similar safety profile except for an increase in ublituximab-related infusion reactions.

Results from this interim analysis suggest no benefit to radiotherapy in elderly DLBCL patients who are PET negative for bulky disease after immunochemotherapy.

Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.

Addition of elotuzumab to RVD associated with high level of overall response in newly diagnosed patients with MM but higher than expected toxicity.

KCd use was associated with a lower rate of nonhematologic AEs and improved odds for PBSC mobilization vs KRd use.

Results of this large international phase III trial showed that denosumab was associated with significantly less renal toxicity and prolonged PFS vs zoledronic acid in patients with newly diagnosed MM.

Phase I results suggest isatuximab-based combination safe, clinically active in highly treatment-experienced R/R MM.

In this expert analysis, Sagar Lonial, MD; John M. Burke, MD; and Farhad Ravandi, MD, review key data from the most clinically relevant studies on the management of hematologic malignancies presented at the 2017 Clinical Oncology annual meeting in Chicago.

John M. Burke, MD Sagar Lonial, MD Farhad Ravandi, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: August 18, 2017 Expired: No longer available for credit

Adjuvant gefitinib for up to 2 years achieved superior DFS vs vinorelbine/cisplatin with no cases of interstitial lung disease.

Nivolumab with or without ipilimumab associated with durable responses in patients with advanced, previously treated SCLC.

Patients with high PD-L1 who started treatment with first-line pembrolizumab achieved better survival outcomes than those starting with first-line chemotherapy.

Patients who remained on atezolizumab after progression of disease by RECIST continued to derive benefit.

Osimertinib associated with significantly improved CNS disease control vs platinum/pemetrexed in patients with CNS metastases from advanced NSCLC.

One half of patients with irAE-related dose interruptions experienced recurrent or new irAEs during immunotherapy retreatment.

nab-Paclitaxel–based treatment was active and well tolerated in elderly patients and those with poorer ECOG performance status.

Pembrolizumab plus chemotherapy significantly improved ORR and PFS vs chemotherapy alone with comparable safety profile.

Matthew D. Hellmann, MD, and Heather Wakelee, MD, examine and discuss key lung cancer and mesothelioma presentations from the 2017 clinical oncology meeting in Chicago.

Matthew D. Hellmann, MD Heather Wakelee, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: August 10, 2017 Expired: No longer available for credit

Nivolumab with and without ipilimumab was associated with 12-week disease control rates > 40% and median OS > 10 months in patients who progressed after 1-2 lines of chemotherapy.

In this phase III study, dacomitinib demonstrated superior PFS and DoR, but with increased toxicity, vs gefitinib in treatment-naive patients with advanced NSCLC and EGFR-activating mutations.

Alectinib increased median PFS more than 2-fold and delayed CNS progression with favorable toxicity compared with crizotinib.

Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.

In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.

A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.

First presentation of efficacy data suggests checkpoint inhibitor combination is effective in these patients, with intracranial ORR of 55%.

Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.